Olivier Le Moal Thesis Based on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)'s imminent catalysts (Reproxalap), considering the company holds $133 million in cash, cash equivalents and marketable securities, as per March 31st, with a market cap around$230 million, I believe ALDX is still trading at a discount. Hence, in my opinion, Aldeyra offers a high-risk/high-reward investment opportunity, which supports a "Strong Buy" rating for investors with high risk tolerance. In this article, I will be explaining the ...